Clinical trials: TAS 102
Colorectal Cancer
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
- Trial name
- NCT05343013
- Testing
- TAS-102
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
This phase II study aims to explore the efficacy and safety of fruquintinib combined with TAS-102 in the third-line treatment of patients with advanced metastatic colorectal cancer.
- Trial name
- NCT05004831
- Testing
- fruquintinib plus TAS-102
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
This phase II trial studies how well trifluridine/tipiracil and oxaliplatin work as the first line of treatment (induction) in treating patients with esophageal or gastroesophageal junction adenocarcinoma that can be removed by…
- Conditions
- Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04097028
- Testing
- Trifluridine and Tipiracil Hydrochloride, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumors (Excluding Breast Cancer)
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
The purpose of this study is to compare the bioavailability of TAS-102 tablets to an oral solution containing equivalent amounts FTD and TPI.
- Trial name
- NCT01874522
- Testing
- TAS-102 tablets, TAS-102 oral solution
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer Metastatic
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102…
- Trial name
- NCT02286492
- Testing
- TAS-102
- Where
- 33 sites in United States
- Sponsor
- Taiho Oncology, Inc.
Metastatic Colorectal Cancer
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC).
- Trial name
- PRECONNECT (NCT03306394)
- Testing
- Trifluridine/Tipiracil hydrochloride (S95005)
- Where
- 99 sites in Australia, Belgium and 14 more
- Volunteers
- 907 people
- Sponsor
- Institut de Recherches Internationales Servier
Colorectal Cancer
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared…
- Trial name
- AndroMETa-CRC (NCT07525206)
- Testing
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 990 people
- Sponsor
- AbbVie
Colorectal Cancer, Metastatic Colorectal Cancer
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Refractory Colorectal Carcinoma
- Trial name
- NCT06221423
- Testing
- Fruquintinib Combined With TAS-102
- Where
- China
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in…
- Trial name
- NCT05608044
- Testing
- Botensilimab, Balstilimab, Standard of Care
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 234 people
- Sponsor
- Agenus Inc.
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
In mCRC, response to second-line chemotherapy is limited, and few treatment options are available. It is urgent to design an optimal second-line treatment regimen to improve the response rate and prolong the survival of patients…
- Trial name
- NCT06202001
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
- Trial name
- TERRA (NCT01955837)
- Testing
- TAS-102
- Where
- 4 sites in China, South Korea and 1 more
- Volunteers
- 406 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma
This is a single-arm, non-randomised study including patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease not amenable to curative treatment, who have received at least 1 regimen of platinum…
- Trial name
- NCT04627961
- Testing
- TAS-102
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- National University Hospital, Singapore
Refractory Metastatic Colorectal Cancer
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
- Trial name
- NCT02860546
- Testing
- TAS-102, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
ESCC, TAS 102
TAS-102 Plus Radiotherapy in Elderly ESCC
This study is a single-arm, multicenter clinical trial evaluating the efficacy and safety of radiotherapy combined with TAS-102 monotherapy in elderly patients with locally advanced esophageal cancer.
- Conditions
- ESCC, TAS 102, Radiotherapy
- Trial name
- NCT07196345
- Testing
- TAS-102, Radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Qianfoshan Hospital
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
This phase 1b trial studies the side effects and best dose of TAS-102 when given together with radiation therapy in treating patients with stage II-III rectal cancer that has not been treated and can be removed by surgery…
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT04104139
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Colorectal Cancer
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
- Trial name
- ALEXANDRIA (NCT02654639)
- Testing
- TAS-102, Bevacizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Georgetown University
Pancreatic Neoplasms
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer
- Trial name
- NCT05481463
- Testing
- Surufatinib, TAS-102
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sun Yat-sen University
Gastric Adenocarcinoma, GastroEsophageal Cancer
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma.
- Trial name
- NCT04074343
- Testing
- TAS-102, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Rectal Adenocarcinoma
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
A Prospective Single-Arm Study of Short-Course Radiotherapy Followed by PD-1 Monoclonal Antibody, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil for Total Neoadjuvant Therapy in MSS Locally Advanced Low Rectal Cancer.
- Trial name
- SCRIPBOT (NCT06872606)
- Testing
- Pucotenlimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Metastatic Colorectal Cancer
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
The main purpose of this study is to assess the safety and tolerability and to determine the recommended phase 2 dose of S 95005 given in combination with oxaliplatin in patients with metastatic colorectal cancer.
- Trial name
- NCT02848443
- Testing
- Trifluridine/tipiracil hydrochloride (S 95005), Oxaliplatin, Bevacizumab
- Where
- 24 sites in Austria, France and 5 more
- Volunteers
- 78 people
- Sponsor
- Institut de Recherches Internationales Servier